Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning Risk and Accompaniment of Patients' With Cancer (PROADAPT)

August 24, 2023 updated by: Hospices Civils de Lyon

Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning Risk and Accompaniment of Patients' With Cancer, a Multicenter Pilot Study

With the conjunction of increased life expectancy and the increasing incidence of cancer with aging, older patient represent an increasing proportion of cancer patients. Increasing age is also associated with increased risk of co-morbidities as well as a decline of functional reserve of multiple organ systems, eventually leading in the context of the disease-and/or the treatment-related stress to functional deconditioning or organ failure.

Surgery or complex medico-surgical procedures - that associate chemotherapy and/or radiotherapy and surgery, can be considered as one proof-of principle of such risks, since major cancer surgery the older population is at higher risk of morbi-mortality and unplanned hospitalization for geriatric events In order to reduce complications after surgery, prehabilitation has often been considered, and 71% of the surgeons would accept a 4 weeks delay before surgery to improve patients' outcomes if shown to be beneficial. However, the actual level of evidence depends on the interventions: high for pre-operative nutrition, but low for physical exercise, due to heterogeneous programs with often bad adherence. In addition, geriatric validated interventions, in order to prevent iatrogenic event, may be added in a multi-interventional model of intervention.

Study Overview

Status

Completed

Conditions

Detailed Description

PROADAPT pilot study is a standardized geriatric intervention constructed on a multi-professional and multi-disciplinary basis after a systematic analysis of published data.

This intervention was designed to be implemented pragmatically in the centers according local habits in several distinct hospital contexts in different tumor contexts.

It consists in:

  1. before surgery: a prehabilitation of the patients including a nutritional, physical and educational preparation;
  2. during the hospitalization for surgery: an optimisation of their treatments through a pharmaceutical conciliation, educational interventions, standardization of surgical procedures and enhanced rehabilitation after surgery;
  3. bridging and post-discharge interventions for hospital-to-home transition.

Study Type

Interventional

Enrollment (Actual)

148

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chambéry, France
        • Centre Hospitalier de Chambéry
      • Givors, France
        • Centre hospitalier de Givors
      • Lyon, France
        • Hopital Croix Rousse
      • Lyon, France
        • Centre Hospitalier Edouard Herriot
      • Metz-Tessy, France
        • Centre Hospitalier d'Annecy Genevois
      • Pierre-Bénite, France
        • Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale
      • Pierre-Bénite, France
        • Centre Hospitalier Lyon Sud, Service de Gériatrie
      • Saint-Étienne, France
        • Centre Hospitalier Universitaire de Saint Etienne
      • Villefranche-sur-Saône, France
        • Hôpital Nord-Ouest
      • Villeurbanne, France
        • Clinique mutualiste Médipole

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient ≥70 year old OR patient ≥60 years with significant comorbid condition (modified Charlson index≥3) or disability (ADL score<6/6);
  • Histologically or cytologically proven cancer.
  • Life expectancy > 3 months.
  • Written informed consent obtained
  • Covered by a Health System where applicable.

Exclusion Criteria:

  • Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
  • Patient unable to be regularly followed for any reason (geographic, familial, social, psychologic).
  • Any mental or physical handicap at risk of interfering with the appropriate treatment.
  • Any administrative or legal supervision where applicable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention

The intervention is designed to be implemented at different times of patients' care

During the prehabilitation time:

  • Nutritional care
  • Total-body rehabilitation
  • Pharmaceutical conciliation During peri-operative time
  • Management of enhances rehabilitation of the elderly. During rehabilitation time
  • Nutritional, medication conciliation and functional follow-up During hospital-home transition time
  • Nutritional and functional follow-up
  • Optimisation of symptoms management: abdominal pain, nausea, vomiting…

Nutritional care is based on:

  • A personalized evaluation of nutritional balance and nutritional needs of the patient
  • A weekly follow-up of weight and nutritional intake

Total-body rehabilitation is based on:

  • 2 to 3 times a week: strength exercise
  • 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence
  • 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Preoperative physical activity including strength and endurance exercise assessed by physical exercises accomplished under the supervision of a physiotherapist. Number of patients with at least 1 intervention achieved in the domain.
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Nutrition guidelines before and after physical activity assessed by questionnaires. Number of patients with at least 1 intervention achieved in the domain.
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Patient education and coaching assessed by questionnaires and visits. Number of patients with at least 1 intervention achieved in the domain
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Achievement of standardized intervention procedures, according to the checklist established in consensus with surgeons. Number of patients with at least 1 intervention achieved in the domain
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Rehabilitation assessed by questionnaires. Number of patients with at least 1 intervention achieved in the domain
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Accomplishment of pharmaceutical medication conciliation and treatment optimization. Number of patients with at least 1 intervention achieved in the domain
12 months
Implementation of at least one item of PROADAPT standardized geriatric intervention of the program PROADAPT pilot study
Time Frame: 12 months
Bridging interventions for hospital-to-home transition. Number of patients with at least 1 intervention achieved in the domain
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival
Time Frame: 12 months
12 months
Post operative morbidity
Time Frame: 30 and 90 days
Post operative morbidity according Clavien-Dindo classification
30 and 90 days
Post-operative morbidity
Time Frame: 90 days
Post-operative morbidity according to NCI CTC v4.4
90 days
Therapeutic strategy
Time Frame: 12 months
Treatment plan completion rate: Number of patients for whom the treatment plan was completed.
12 months
Post-treatment complication
Time Frame: 12 months
Post-treatment complication grade≥3 according the National Cancer Institute Common Toxicity Criteria version 4 (NCI-CTC-v4)
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Claire FALANDRY, MD, Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 3, 2018

Primary Completion (Actual)

April 27, 2023

Study Completion (Actual)

April 27, 2023

Study Registration Dates

First Submitted

June 1, 2018

First Submitted That Met QC Criteria

September 3, 2018

First Posted (Actual)

September 6, 2018

Study Record Updates

Last Update Posted (Actual)

August 25, 2023

Last Update Submitted That Met QC Criteria

August 24, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 69HCL16_0701

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Old Injury

Clinical Trials on standardized geriatric intervention

3
Subscribe